AC Immune (ACIU) Cash from Financing Activities (2016 - 2025)
AC Immune has reported Cash from Financing Activities over the past 10 years, most recently at -$326555.3 for Q4 2025.
- Quarterly Cash from Financing Activities fell 45.21% to -$326555.3 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$706846.9 through Dec 2025, up 85.0% year-over-year, with the annual reading at -$1.3 million for FY2025, 0.18% changed from the prior year.
- Cash from Financing Activities was -$326555.3 for Q4 2025 at AC Immune, down from $205018.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $46.3 million in Q4 2023 and troughed at -$3.6 million in Q3 2024.
- The 5-year median for Cash from Financing Activities is -$144640.5 (2022), against an average of $4.3 million.
- Year-over-year, Cash from Financing Activities soared 29609.2% in 2023 and then plummeted 815.68% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at $31.2 million in 2021, then crashed by 100.5% to -$156741.3 in 2022, then soared by 29609.2% to $46.3 million in 2023, then crashed by 100.49% to -$224879.8 in 2024, then plummeted by 45.21% to -$326555.3 in 2025.
- Per Business Quant, the three most recent readings for ACIU's Cash from Financing Activities are -$326555.3 (Q4 2025), $205018.0 (Q3 2025), and -$298348.9 (Q2 2025).